MetaVia Inc.

METABODY AI INC.AI/MLUnited States

67% match

Metabody AI Inc. provides a continuous, closed-loop metabolic health platform that combines wearable and lab data integration with an AI co-clinician and a network of licensed healthcare providers. The platform serves individuals and employers by unifying health metrics, providing proactive guidance, and facilitating clinician-led care across all 50 states.

GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.

MedWellAI Inc., through its subsidiary, develops, acquires, operates, and invests in businesses. It provides AI-driven healthcare and wellness solutions. The company also offers a B2B e-commerce platform for distributing pharmaceutical products, particularly GLP medications for weight loss and diabetes management. In addition, it provides an AI-powered ordering system with inventory tracking, smart suggestions, and support for healthcare providers such as wellness clinics, med spas, and corporate wellness facilities. The company was formerly known as Integrated Ventures, Inc. and changed its name to MedWellAI Inc. in June 2025. The company is based in Clearwater, Florida.

BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.

Enjamb LabsAI/MLUnited States

62% match

Enjamb Labs provides an AI-powered agentic workspace designed for biopharma teams to manage drug development programs from discovery through FDA approval. Its platform integrates specialized AI agents to handle clinical evidence, trial design, statistical programming, and regulatory submissions within existing enterprise systems.